More Affordable Medicines for Patients
We drive early market entries at best prices
Get a reliable, flexible, and cost-efficient supply!
We, at Tiefenbacher Pharmaceuticals, strongly believe that our high-quality medicines should be affordable for all patients irrespective of their income level. That´s why we strive for these two goals:
- Achieving an earliest possible market entry for our customers
Tiefenbacher Pharmaceuticals is well known for its highly rated research & development competence, quality excellence, and regulatory expertise – being the foundation for a constant track record of first-to-file dossiers. - Driving efficiency in our supply chains to offer best possible prices
We drive efficiency by keeping our supply chains simple and reaching economies of scale in our own manufacturing sites. Most modern supply chain solutions and a lean management approach ensure that our affordable products reach the right place in the right condition and quantity on time.
Our Expertise
Our success factors for early market entries at best prices
Driving efficient supply chains and early market entries in multiple disease areas for affordable healthcare worldwide.
Tiefenbacher MAnufacturing site in cyprus
Large-scale production in Europe
Tiefenbacher´s state-of-the-art manufacturing facilities on Cyprus have been designed to accommodate the bulk production as well as primary and secondary packaging operations of non-sterile oral solid dosage forms. The production and packaging lines are equipped with sophisticated technology from the first manufacturing step throughout to the last packaging step and are flexible to manage small batch as well as high volume productions.
- Tablets, capsules, and powder suspensions for reconstitution
- EU batch testing and release of pharmaceutical products
- ICH stability studies for all zones
- Many analytical laboratory services
- Technology transfer
- Import/storage/warehousing
- GMP compliance and relevant ISO certifications
Tiefenbacher LAboratories manufacturing site in India
Differentiated speciality production - FDA inspected
- Manufacturing, testing, packing, warehousing, and releasing of tablets and capsules in a GMP compliant environment
- Successfully inspected by German and US authorities
- New state-of-the-art site for highly potent drugs
- Modern technologies like dry, wet, top spray and hot melt granulation
- Blister and bottle packaging
We are best practice
Successful day-one-launch of Posaconazole
In 2019 AET successfully launched the first generic product of Posaconazole, a therapeutically equivalent version of the originator product Noxafil®. Studies have demonstrated the satisfactory quality of the product and its bioequivalence to the reference product. Posaconazole is effectively used for the treatment of several fungal infections. With this first-to-market entry in nine European countries, AET achieved nameable savings for the international health care systems and enabled millions of patients a better affordable access to this life-improving treatment. Following our global market entry approach, a launch in about 60 further international countries is already in progress.
Posaconazole has been developed and manufactured in TIEFENBACHER´s own laboratory and manufacturing sites under strictest safety and quality guidelines. An efficiency-driven supply chain approach as well as our highly rated development and regulatory expertise were important pillars for this successful day-one-launch.